Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Autoimmune Diseases

PhRMA Honors 2016 Research & Hope Award Recipients; Focus Is on Autoimmune Diseases

phrma-logo-whiteWashington, DC, September 15, 2016 — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced the recipients of the 2016 Research & Hope Awards.

This year, PhRMA recognized patient advocates and researchers for their tireless efforts to advance the treatment and care of patients with autoimmune diseases, a group of more than 80 diseases in which a person’s own immune system attacks the body’s healthy cells.

PhRMA was joined by 22 patient and community health organizations in honoring the 2016 award winners at an annual dinner in Washington, D.C., on September 13, featuring a keynote address by actress Jamie-Lynn Sigler, best known for her role in the HBO television series “The Sopranos.” Continue reading

PhRMA and Lupus Foundation of America Report: 311 Medicines in Development for Autoimmune Diseases

Research 1Washington, DC, September 14, 2016 — A new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA) and Lupus Foundation of America highlights tremendous progress in the fight against autoimmune diseases.

According to the report, “Medicines in Development For Autoimmune Diseases,” America’s biopharmaceutical research companies have 311 medicines and vaccines in clinical trials or pending review by the U.S. Food and Drug Administration for patients with autoimmune diseases.

There remains a lot to be learned about autoimmune diseases and their cause, but biopharmaceutical companies are leading efforts to demystify these diseases. Continue reading